Weight Loss Guide

Tirzepatide for Weight Loss

FDA-approved dual-agonist (sold as Mounjaro and Zepbound). The best balance of weight loss efficacy, safety data, and tolerability currently available.

Education only: This page describes what clinical trials and the FDA-approved labeling report. It is not medical advice and not a dosing protocol. Dose selection and any change to a regimen are decisions for a licensed prescriber. Nothing here tells you to start, stop, or adjust a dose.

22.5%

Avg Weight Loss

72 weeks

Trial Duration

Weekly

Frequency

FDA Approved

Status

Why Tirzepatide is the Most Popular Choice

Extensive Safety Data

FDA-approved with large Phase 3 SURMOUNT trials involving thousands of participants. Most well-studied weight loss peptide available.

Excellent Tolerability

The GIP component reduces nausea significantly compared to GLP-1-only drugs. Most users find it better tolerated than equivalent-dose Semaglutide.

Proven Results

22.5% average weight loss in SURMOUNT-1 trial. 87% of participants achieved at least 5% weight loss. Real-world results consistently match trials.

How the Approved Label Titrates Tirzepatide

Phase	Dose	Duration	Expected Effect
Starting	2.5mg	Weeks 1 to 4	Tolerance building, mild appetite changes
Titration 1	5mg	Weeks 5 to 8	Clear appetite suppression, first weight loss
Titration 2	7.5mg	Weeks 9 to 12	Accelerated fat loss
Titration 3	10mg	Weeks 13 to 16	Near maximum therapeutic effect
Target	10 to 15mg	Ongoing	Maintenance and continued loss

This reproduces the dose escalation in the FDA-approved labeling for tirzepatide (Mounjaro and Zepbound). It is published prescribing information shown for education, not a personal protocol. The actual dose and any change to it are decisions a licensed prescriber makes. Generic research tirzepatide is also a different presentation than pharmaceutical pens, so mg per unit can differ.

Expected Results Timeline

2.5mg Phase

Subtle appetite changes. Some users notice less interest in food. Minimal weight loss at this dose, it's primarily a tolerance-building phase.

5 to 7.5mg Phase

Clear, noticeable appetite suppression. Food intake drops naturally. Weight loss becomes consistent, typically 0.5 to 1.5kg per week.

10 to 15mg Phase

Maximum weight loss phase. Many users describe near-complete suppression of hunger. Rapid body composition changes. 10 to 20% total loss achievable.

Long-term

Weight loss slows as body weight decreases (fewer calories to cut). Maintenance becomes the goal. Many users stay at 10mg long-term.

Not Losing Weight?

If you are not losing weight at a starting dose, that is expected. Starting doses build tolerance, they are not the weight-loss dose. Whether and when a dose moves up is a prescriber decision, not a self-directed step.

If weight stalls once you are on a maintenance dose, track actual caloric intake. Tirzepatide suppresses hunger but does not prevent eating above maintenance.

In the trials, tirzepatide is given by subcutaneous injection. Route and technique are things a prescriber or pharmacist covers, not something to improvise.

Storage affects potency. A broken cold chain, or freezing after reconstitution, is a known cause of a weak response.

Verify COA and product authenticity, underdosed or counterfeit product is a common cause.

Medical causes: thyroid issues, medications that cause weight gain, or metabolic adaptation, consult a doctor.

Rebound Warning: Weight typically returns if Tirzepatide is discontinued without lifestyle changes. The peptide suppresses appetite, when stopped, appetite returns to baseline. Maintain dietary habits and exercise routine learned during treatment.

Sourcing research-grade tirzepatide? Compare lab-tested options with per-batch certificates of analysis at Peptara Labs, then verify any supplier against a COA before you buy.

Full Tirzepatide Guide Compare: Retatrutide Compare: Semaglutide Not Losing Weight FAQ View Supply Index